Mechanism and Inhibition of saFabI, the Enoyl Reductase from Staphylococcus aureus.

Mechanism and Inhibition of saFabI, the Enoyl Reductase from Staphylococcus aureus. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Mechanism and Inhibition of saFabI, the Enoyl Reductase from Staphylococcus aureus. Abstract Text:

Hua Xu,Todd J Sullivan,Jun-Ichiro Sekiguchi,Teruo Kirikae,Iwao Ojima,Christopher F Stratton,Weimin Mao,Fernando L Rock,M R K Alley,Francis Johnson,Stephen G Walker,Peter J Tonge,

Approximately one-third of the world's population carries Staphylococcus aureus. The recent emergence of extreme drug resistant strains that are resistant to the "antibiotic of last resort", vancomycin, has caused a further increase in the pressing need to discover new drugs against this organism. The S. aureus enoyl reductase, saFabI, is a validated target for drug discovery. To drive the development of potent and selective saFabI inhibitors, we have studied the mechanism of the enzyme and analyzed the interaction of saFabI with triclosan and two related diphenyl ether inhibitors. Results from kinetic assays reveal that saFabI is NADPH-dependent, and prefers acyl carrier protein substrates carrying fatty acids with long acyl chains. On the basis of product inhibition studies, we propose that the reaction proceeds via an ordered sequential ternary complex, with the ACP substrate binding first, followed by NADPH. The interaction of NADPH with the enzyme has been further explored by site-directed mutagenesis, and residues R40 and K41 have been shown to be involved in determining the specificity of the enzyme for NADPH compared to NADH. Finally, in preliminary inhibition studies, we have shown that triclosan, 5-ethyl-2-phenoxyphenol (EPP), and 5-chloro-2-phenoxyphenol (CPP) are all nanomolar slow-onset inhibitors of saFabI. These compounds inhibit the growth of S. aureus with MIC values of 0.03-0.06 microg/mL. Upon selection for resistance, three novel safabI mutations, A95V, I193S, and F204S, were identified. Strains containing these mutations had MIC values approximately 100-fold larger than that of the wild-type strain, whereas the purified mutant enzymes had K i values 5-3000-fold larger than that of wild-type saFabI. The increase in both MIC and K i values caused by the mutations supports the proposal that saFabI is the intracellular target for the diphenyl ether-based inhibitors.

Mechanism and Inhibition of saFabI, the Enoyl Reductase from Staphylococcus aureus. Publishing Authors By Initials

H Xu,TJ Sullivan,J Sekiguchi,T Kirikae,I Ojima,CF Stratton,W Mao,FL Rock,MR Alley,F Johnson,SG Walker,PJ Tonge,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Mechanism and Inhibition of saFabI, the Enoyl Reductase from Staphylococcus aureus. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Biochemistry

VOLUME: 47

Page Numbers: 4228-36

Journal Abbreviation: Biochemistry

ISSN: 0006-2960

DAY: 13

MONTH: 03

YEAR: 2008

Mechanism and Inhibition of saFabI, the Enoyl Reductase from Staphylococcus aureus. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370623

Mechanism and Inhibition of saFabI, the Enoyl Reductase from Staphylococcus aureus. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Mechanism and Inhibition of saFabI, the Enoyl Reductase from Staphylococcus aureus. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Mechanism and Inhibition of saFabI, the Enoyl Reductase from Staphylococcus aureus.

AFFILIATION: peter.tonge@sunysb.edu.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Biochemistry

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Mechanism and Inhibition of saFabI, the Enoyl Reductase from Staphylococcus aureus Related Publications

• Aneurysms of the splenic artery, with a report of two cases and review of the literature.
• Brief report: Inhibition of return in young people with autism and Asperger's disorder.
• Crime in the search of truth.
• Dietary management of acute oliguric renal failure.
• Evidence from Raman spectroscopy that InhA, the mycobacterial enoyl reductase, modulates the conformation of the NADH cofactor to promote catalysis.
• High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
• Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway.
• Mechanism and Inhibition of saFabI, the Enoyl Reductase from Staphylococcus aureus.
• Observation of excited-state proton transfer in green fluorescent protein using ultrafast vibrational spectroscopy.
• Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
• Short form of the developmental behaviour checklist.
• Structure and mechanism of MbtI, the salicylate synthase from Mycobacterium tuberculosis.
• Structure of acyl carrier protein bound to FabI, the FASII enoyl reductase from Escherichia coli.
• The neurasthenic psychopath.
• Translation and Australian validation of the spinal cord lesion-related coping strategies and emotional wellbeing questionnaires.